Vyluma Announces FDA Acceptance of New Drug Application For NVK002, Its Novel Investigational Treatment For Pediatric Myopia

Bridgewater, NJ– June 6, 2023– Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has...

https://www.drugs.com/nda/nvk002_230606.html

Source: Drugs.com - New Drug Applications - June 6, 2023 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Myopia (short sighted) | New Drug Applications | Pediatrics